Hiroyuki Inoue

Dr. Hiroyuki Inoue

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Lung Cancer
Verified
Journal Article
Closed access
RFRie Furukawa
Rie Furukawa
HIHiroyuki Inoue
Hiroyuki Inoue
YYYasuto Yoneshima
Yasuto Yoneshima
HTHirono Tsutsumi
Hirono Tsutsumi
EIEiji Iwama
Eiji Iwama
IOIsamu Okamoto
Isamu Okamoto

6 March 2020 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TOTomokazu Ohishi
Tomokazu Ohishi
HAHikaru Abe
Hikaru Abe
CSChiharu Sakashita
Chiharu Sakashita
USUzma Saqib
Uzma Saqib
MBMirza Baig
Mirza Baig
MKManabu Kawada
Manabu Kawada
Modulation of prostate stromal cells (PrSCs) within tumor tissues is gaining attention for the treatment of solid tumors. Using our original in vitro coculture system, we previously reported that leucinostatin (LCS)‐A, a peptide mycotoxin, inhibited prostate cancer DU‐145 cell growth through reduction of insulin‐like growth factor 1 (IGF‐I) expression in PrSCs. To further obtain additional bioactive compounds from LCS‐A, we designed and synthesized a series of LCS‐A derivatives as compounds that target PrSCs. Among the synthesized LCS‐A derivatives, LCS‐7 reduced IGF‐I expression in PrSCs with lower toxicity to PrSCs and mice than LCS‐A. As LCS‐A has been suggested to interact with mitochondrial adenosine triphosphate (ATP) synthase, a docking study was performed to elucidate the mechanism of reduced IGF‐I expression in the PrSCs. As expected, LCS‐A and LCS‐7 directly interacted with mitochondrial ATP synthase, and like LCS‐A and LCS‐7, other mitochondrial ATP synthase inhibitors also reduced the expression of IGF‐I by PrSCs. Furthermore, LCS‐A and LCS‐7 significantly decreased the growth of mouse xenograft tumors. Based on these data, we propose that the mitochondrial ATP synthases–IGF‐I axis of PrSCs plays a critical role on cancer cell growth and inhibition could be a potential anticancer target for prostate cancer.

12 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAkira Sakamoto
Akira Sakamoto
HIHiroyuki Inoue
Hiroyuki Inoue
SMShohei Miyamoto
Shohei Miyamoto
SIShun Ito
Shun Ito
YSYasushi Soda
Yasushi Soda
KTKenzaburo Tani
Kenzaburo Tani
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Innovative treatment is required to improve overall survival rates for advanced NSCLC. Oncolytic virotherapy using enteroviruses has emerged as a promising anticancer strategy. To identify a novel, potent virotherapy with an improved safety profile, we assessed the oncolytic activity of 28 enteroviral strains and focused on coxsackievirus A11 (CVA11). CVA11 infection caused extensive oncolytic activity in all three of the examined human NSCLC cell lines, with high intercellular adhesion molecule-1 (ICAM-1) expression associated with greater CVA11-induced cytotoxicity. In vitro inhibition analysis using a pan-caspase inhibitor and western blot detection of cleaved poly (ADP-ribose) polymerase (PARP) indicated that apoptosis partly contributed to CVA11-driven cytotoxicity. CVA11 infection-induced immunogenic cell death in vitro was strongly suggested by substantial calreticulin expression and release of high mobility group box-1 protein (HMGB1). Moreover, in vivo treatment of human NSCLC xenografts with intratumoral CVA11 injection caused complete tumor regression in all treated mice, without significant weight loss. Our findings indicate that novel oncolytic virotherapy utilizing CVA11 may be less toxic and more effective than current treatments for human NSCLC, thus warranting further investigation in clinical trial settings, especially in combination with immunotherapy.

25 January 2023 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
NINobumitsu Ikeuchi
Nobumitsu Ikeuchi
FIFumiyasu Igata
Fumiyasu Igata
EKEriko Kinoshita
Eriko Kinoshita
TKToshiaki Kawabata
Toshiaki Kawabata
ITIbun Tan
Ibun Tan
HIHiroyuki Inoue
Hiroyuki Inoue
Background/Aim: Platinum-doublet chemotherapy plus either programmed cell death 1 (PD-1) or programmed death ligand 1 (PD-L1) checkpoint inhibitors has been reported to improve the survival of patients with advanced non-small cell lung cancer (NSCLC). The IMpower150 study showed significant improvements in progression-free survival and overall survival with atezolizumab in combination with bevacizumab, a humanized anti-VEGF monoclonal antibody, paclitaxel, and carboplatin (ABCP therapy) in chemotherapy-naïve patients with non-squamous NSCLC. We herein report the efficacy and safety of ABCP therapy in Japanese patients with non-squamous NSCLC in clinical practice. Patients and Methods: We retrospectively evaluated the efficacy and safety of ABCP therapy in 30 patients treated at our hospital from February 2019 to December 2021. Results: The median age of patients was 69 years, 24 (80.0%) patients were male, 29 (96.7%) patients had a performance status of 0 or 1, 28 (93.3%) patients had adenocarcinoma histology, and 7 (23.3%) patients had epidermal growth factor receptor mutations. Evaluation of the PD-L1 tumor proportion score (TPS) showed that 12 (40.0%), 8 (26.7%), and 6 (20.0%) patients had a TPS of ≥50%, 1% to 49%, and <1%, respectively. The objective response rate of the intention-to-treat wild-type population was 73.9%, and the median progression-free survival was 8.3 months. Immune checkpoint inhibitor (ICI)-induced pneumonitis occurred in one (3.3%) patient. Conclusion: ABCP therapy for Japanese non-squamous NSCLC patients in a clinical setting achieved a high response rate with low incidence of ICI-induced pneumonitis equivalent to those observed in IMpower150 study.

26 June 2024 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
FIFumiyasu Igata
Fumiyasu Igata
HIHiroyuki Inoue
Hiroyuki Inoue
TITakato Ikeda
Takato Ikeda
ANAkira Nakao
Akira Nakao
NENoriyuki Ebi
Noriyuki Ebi
MFMasaki Fujita
Masaki Fujita
Background/Aim: The combination of programmed cell death ligand 1 inhibitors and platinum-based chemotherapy has become the standard treatment for first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC). This study compared the efficacy and safety of atezolizumab plus chemotherapy and durvalumab plus chemotherapy in the treatment of ES-SCLC in clinical practice. Patients and Methods: We retrospectively analyzed 40 patients with ES-SCLC treated with atezolizumab plus chemotherapy or durvalumab plus platinum-based chemotherapy at the Fukuoka University Hospital between October 2019 and November 2022. Results: Among the 40 patients, 20 were treated with atezolizumab and 20 were treated with durvalumab. There was no significant difference in patient characteristics between the two groups; five patients who received atezolizumab and one who received durvalumab showed a performance status of 2 or higher. The median progression-free survival of patients who received atezolizumab or durvalumab was 5.6 and 5.4 months, respectively (p=0.881). The median overall survival of patients who received atezolizumab or durvalumab was 10.0 and 17.1 months, respectively (p=0.163). The objective response rate of the patients who received atezolizumab or durvalumab was 80.0% and 85.0%, respectively. There was no significant difference in the incidence of immune-related adverse events between the groups. Conclusion: This retrospective study was the first to compare the efficacy and safety of PD-L1 antibody, atezolizumab or durvalumab, in combination with carboplatin and etoposide in treatment-naïve ES-SCLC Japanese patients in a real-world setting. Both regimens, atezolizumab or durvalumab with carboplatin and etoposide, were effective and well-tolerated in Japanese ES-SCLC patients, in line with clinical trial findings.

1 January 1994 in Journal of Toxicologic Pathology
Verified
Journal Article
Open access
YHYasuhiko Hirouchi
Yasuhiko Hirouchi
HIHijiri Iwata
Hijiri Iwata
SYSeiki Yamakawa
Seiki Yamakawa
MKMutsumi Kato
Mutsumi Kato
KKKazuo Kobayashi
Kazuo Kobayashi
YKYoshihide Koike
Yoshihide Koike